Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
357 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-11-30
Study Completion Date
2028-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized, double-blind, placebo-controlled trial in 2 parts evaluating the effect of 1-time administration of the monoclonal antibody (MAb) L9LS to healthy Malian participants on the immunogenicity of subsequent administration of the R21/Matrix-M™ vaccine. L9LS will be administered subcutaneously (SC) for adults and infants. The study will assess how the timing of L9LS administration impacts immunogenicity following subsequent intramuscular (IM) R21/Matrix-M™ vaccination. Twenty-four adult participants and 333 infant participants will be enrolled.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-malaria MAb in Malian Children
NCT05304611
Plasmodium Falciparum Infection
Malaria
COMPLETED
PHASE2
L9LS MAb in Malian Adults
NCT05816330
Plasmodium Falciparum Infection
Malaria
COMPLETED
PHASE2
L9LS in Women of Childbearing Potential in Mali
NCT07060508
Malaria
RECRUITING
PHASE2
Trial to Evaluate L9LS in Healthy Adults
NCT05019729
Malaria
COMPLETED
PHASE1
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
NCT06080243
Healthy Women of Child Bearing Potential
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Part 1, 24 adult participants will be randomized 1:1 to receive 1800 mg of L9LS or normal saline placebo at enrollment, followed by the R21/Matrix-M™ 3-dose initial vaccine series starting on day 7. Adult participants will be followed at study visits 7 days after L9LS administration and 7 days after each R21/Matrix-M™ vaccination. If no significant safety concerns arise through 7 days after administration of the first R21/Matrix-M™ vaccine (day 14) per an interim safety review, the study will proceed to Part 2. There will also be study visits 28 and 84 days following the last R21/Matrix-M™ vaccine to assess immune responses.
In Part 2, 333 infant participants will be randomized into 1 of 3 cohorts, each with an L9LS arm and a placebo arm (2:1). The individual cohorts will differ in the timing of the R21/Matrix-M™ 3-dose initial vaccine series (7 days, 2 months, and 4 months between L9LS and first R21/Matrix-M™ respectively). Infant participants will be followed at study visits 7 days after L9LS administration and 7 days after each R21/Matrix-M™ vaccination, after which they will continue to be followed every 28 days through the fourth (booster) dose of the R21/Matrix-M™ vaccine. There will also be study visits 28 and 84 days following the last R21/Matrix-M™ vaccine to assess immune responses. Primary study assessments include medical history, physical examination, and blood collection to assess antibody responses to the R21/Matrix-M™ vaccine, L9LS pharmacokinetics (PK), anti-drug antibody (ADA) assessments, identification of Plasmodium falciparum (Pf) infection by microscopic examination of thick blood smears and reverse transcription polymerase chain reaction (RT-PCR), and other research laboratory evaluations.
In Part 2, 333 infant participants will be randomized into 1 of 3 cohorts, each with an L9LS arm and a placebo arm (2:1). The individual cohorts will differ in the timing of the R21/Matrix-M™ 3-dose initial vaccine series (7 days, 2 months, and 4 months between L9LS and first R21/Matrix-M™ respectively). Infant participants will be followed at study visits 7 days after L9LS administration and 7 days after each R21/Matrix-M™ vaccination, after which they will continue to be followed every 28 days through the fourth (booster) dose of the R21/Matrix-M™ vaccine. There will also be study visits 28 and 84 days following the last R21/Matrix-M™ vaccine to assess immune responses. Primary study assessments include medical history, physical examination, and blood collection to assess antibody responses to the R21/Matrix-M™ vaccine, L9LS pharmacokinetics (PK), anti-drug antibody (ADA) assessments, identification of Plasmodium falciparum (Pf) infection by microscopic examination of thick blood smears and reverse transcription polymerase chain reaction (RT-PCR), and other research laboratory evaluations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Malaria
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
L9LS in Healthy Malian Adult with R21/Matrix-M™ starting 7 days after
L9LS with R21/Matrix-M™ series starting 7 days after.
Group Type
EXPERIMENTAL
Single dose of 1800 mg L9LS SC (12mL)
Intervention Type
DRUG
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo in Healthy Malian Adult with R21/Matrix-M™ starting 7 days after
Placebo with R21/Matrix-M™ series starting 7 days after.
Group Type
PLACEBO_COMPARATOR
Placebo 12 mL SC
Intervention Type
OTHER
Normal saline.
L9LS in Healthy Malian Infant with R21/Matrix-M™ starting 7 days after
L9LS with R21/Matrix-M™ series starting 7 days after.
Group Type
EXPERIMENTAL
Single dose of 225 mg L9LS SC (1.5mL)
Intervention Type
DRUG
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo in Healthy Malian Infant with R21/Matrix-M™ starting 7 days after
Placebo with R21/Matrix-M™ series starting 7 days after.
Group Type
PLACEBO_COMPARATOR
Placebo 1.5 mL SC
Intervention Type
OTHER
Normal saline.
L9LS in Healthy Malian Infant with R21/Matrix-M™ starting 56 days after
L9LS with R21/Matrix-M™ series starting 56 days after.
Group Type
EXPERIMENTAL
Single dose of 225 mg L9LS SC (1.5mL)
Intervention Type
DRUG
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo in Healthy Malian Infant with R21/Matrix-M™ starting 56 days after
Placebo with R21/Matrix-M™ series starting 56 days after.
Group Type
PLACEBO_COMPARATOR
Placebo 1.5 mL SC
Intervention Type
OTHER
Normal saline.
L9LS in Healthy Malian Infant with R21/Matrix-M™ starting 112 days after
L9LS with R21/Matrix-M™ series starting 112 days after.
Group Type
EXPERIMENTAL
Single dose of 225 mg L9LS SC (1.5mL)
Intervention Type
DRUG
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo in Healthy Malian Infant with R21/Matrix-M™ starting 112 days after
Placebo with R21/Matrix-M™ series starting 112 days after.
Group Type
PLACEBO_COMPARATOR
Placebo 1.5 mL SC
Intervention Type
OTHER
Normal saline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Single dose of 1800 mg L9LS SC (12mL)
A human monoclonal antibody to protect against Plasmodium falciparum.
Intervention Type
DRUG
Placebo 12 mL SC
Normal saline.
Intervention Type
OTHER
Single dose of 225 mg L9LS SC (1.5mL)
A human monoclonal antibody to protect against Plasmodium falciparum.
Intervention Type
DRUG
Placebo 1.5 mL SC
Normal saline.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Part 1: Healthy Adults
Individuals must meet all of the following criteria to be eligible for study participation:
1. Male aged ≥18 and ≤50 years weighing ≥50.0 and ≤100.0 kg or female aged ≥18 and ≤50 years weighing ≥45.0 and ≤90.0 kg.
2. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
3. In good general health and without clinically significant medical history.
4. Able to provide informed consent.
5. Willing to have blood samples and data stored for future research.
6. Resides in or near Sotuba, Mali, and available for the duration of the study.
7. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study day 0 through the final study visit as described below.
1. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
2. Nonchildbearing women will be required to report date of last menstrual period, history of surgical sterility (i.e., tubal ligation, hysterectomy) or premature ovarian insufficiency, and will have serum pregnancy test performed per protocol.
Part 2: Healthy Infants
Individuals must meet all of the following criteria to be eligible for study participation:
1. Aged ≥5 and ≤12 months at enrollment.
2. Born at ≥37 weeks gestation (at term).
3. Parent and/or guardian able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
4. In good general health and without clinically significant medical history.
5. Parent and/or guardian able to provide informed consent.
6. Willing to have blood samples and data stored for future research.
7. Resides in or near Sotuba, Mali, and available for the duration of the study.
Individuals must meet all of the following criteria to be eligible for study participation:
1. Male aged ≥18 and ≤50 years weighing ≥50.0 and ≤100.0 kg or female aged ≥18 and ≤50 years weighing ≥45.0 and ≤90.0 kg.
2. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
3. In good general health and without clinically significant medical history.
4. Able to provide informed consent.
5. Willing to have blood samples and data stored for future research.
6. Resides in or near Sotuba, Mali, and available for the duration of the study.
7. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study day 0 through the final study visit as described below.
1. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
2. Nonchildbearing women will be required to report date of last menstrual period, history of surgical sterility (i.e., tubal ligation, hysterectomy) or premature ovarian insufficiency, and will have serum pregnancy test performed per protocol.
Part 2: Healthy Infants
Individuals must meet all of the following criteria to be eligible for study participation:
1. Aged ≥5 and ≤12 months at enrollment.
2. Born at ≥37 weeks gestation (at term).
3. Parent and/or guardian able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
4. In good general health and without clinically significant medical history.
5. Parent and/or guardian able to provide informed consent.
6. Willing to have blood samples and data stored for future research.
7. Resides in or near Sotuba, Mali, and available for the duration of the study.
Exclusion Criteria
Part 1: Healthy Adults
Individuals meeting any of the following criteria will be excluded from study participation:
1. Pregnancy, as determined by a positive urine or serum beta-human choriogonadotropin test (if female).
2. Currently breastfeeding.
3. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the prospective participant to understand and comply with the study protocol.
4. Study comprehension examination score of \<80% correct or per investigator discretion.
5. Hemoglobin, WBC, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
6. ALT or creatinine (Cr) level above the local laboratory-defined upper limit of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
7. Infection with HIV virus.
8. Known or documented sickle cell disease by history. (Note: Known sickle cell trait is NOT exclusionary.)
9. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies.
10. Receipt of any investigational product within the past 30 days.
11. Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit. (Note: Past, current, or planned participation in observational studies is NOT exclusionary; participation in the placebo arm of the Mali adult CIS43LS MAb trial \[ClinicalTrials.gov Identifier: NCT04329104\] or L9LS MAb trials \[NCT05816330\] is NOT exclusionary.)
12. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
13. History of a severe allergic reaction or anaphylaxis, including history of generalized urticaria and angioedema from prior allergic reactions.
14. Hypersensitivity to the active substances or to any of the excipients included in the vaccines.
15. Hypersensitivity to hepatitis B vaccines.
16. Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).
17. Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia.
18. Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
19. Known immunodeficiency syndrome.
20. Known asplenia or functional asplenia.
21. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \>10 mg/day) or immunosuppressive drugs within 30 days of day 0.
22. Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks prior to study agent administration.
23. Receipt of immunoglobulins and/or blood products within the past 6 months.
24. Previous receipt of an investigational malaria vaccine or MAb in the last 5 years.
25. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of an individual participating in the trial, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.
Part 2: Healthy Infants
Individuals meeting any of the following criteria will be excluded from study participation:
1. Body weight \<5.5 kg.
2. Behavioral, cognitive, or psychiatric disease in the parent and/or guardian that in the opinion of the investigator affects the ability of the parent and/or guardian to understand and comply with the study protocol.
3. Any fever (≥ 37.5°C, regardless of route) or acute illness within 7 days prior to randomization.
4. Clinically significant congenital anomaly or documented or suspected serious medical illness (e.g., history of epilepsy), serious congenital anomaly, or immediate life-threatening condition in the infant that may interfere with the ability to complete study requirements, as judged by the examining clinician.
5. Prior history of a suspected or actual acute medically life-threatening event.
6. Receipt of any blood products, monoclonal or polyclonal antibody/immunoglobulin (e.g., hepatitis B immune globulin, IV immunoglobulin), or anticipated use during the study.
7. Any suspected or actual life-threatening acute or chronic illnesses known in the mother during her pregnancy.
8. Parent or guardian study comprehension examination score of \<80% correct or per investigator discretion.
9. Hemoglobin, WBC, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
10. ALT or Cr level above the local laboratory-defined upper limit of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
11. Mother and/or infant infected with HIV.
12. Sickle cell disease by testing. (Note: Known sickle cell trait is NOT exclusionary.)
13. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies.
14. Receipt of any investigational product within the past 30 days.
15. Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit. (Note: Past, current, or planned participation in observational studies is NOT exclusionary.)
16. History of a severe allergic reaction or anaphylaxis, including history of generalized urticaria and angioedema from prior allergic reactions.
17. Hypersensitivity to the active substances or to any of the excipients included in the vaccines.
18. Hypersensitivity to hepatitis B vaccines.
19. Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
20. Pre-existing autoimmune or antibody-mediated diseases including but not limited to systemic lupus erythematosus or autoimmune thrombocytopenia.
21. Known immunodeficiency syndrome.
22. Known asplenia or functional asplenia.
23. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \>10 mg/day) or immunosuppressive drugs within 30 days of day 0.
24. Previous receipt of the R21/Matrix-MTM or RTS,S/AS01 vaccine.
25. Receipt of a live or killed vaccine within the past 1 week prior to study agent administration.
26. Previous receipt of an investigational malaria vaccine or MAb.
27. Previous receipt of L9LS MAb by the mother.
28. Clinical signs of malnutrition.
29. Other condition(s) that, in the opinion of the investigator, might jeopardize the safety or rights of an individual participating in the trial, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.
Individuals meeting any of the following criteria will be excluded from study participation:
1. Pregnancy, as determined by a positive urine or serum beta-human choriogonadotropin test (if female).
2. Currently breastfeeding.
3. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the prospective participant to understand and comply with the study protocol.
4. Study comprehension examination score of \<80% correct or per investigator discretion.
5. Hemoglobin, WBC, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
6. ALT or creatinine (Cr) level above the local laboratory-defined upper limit of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
7. Infection with HIV virus.
8. Known or documented sickle cell disease by history. (Note: Known sickle cell trait is NOT exclusionary.)
9. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies.
10. Receipt of any investigational product within the past 30 days.
11. Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit. (Note: Past, current, or planned participation in observational studies is NOT exclusionary; participation in the placebo arm of the Mali adult CIS43LS MAb trial \[ClinicalTrials.gov Identifier: NCT04329104\] or L9LS MAb trials \[NCT05816330\] is NOT exclusionary.)
12. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
13. History of a severe allergic reaction or anaphylaxis, including history of generalized urticaria and angioedema from prior allergic reactions.
14. Hypersensitivity to the active substances or to any of the excipients included in the vaccines.
15. Hypersensitivity to hepatitis B vaccines.
16. Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).
17. Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia.
18. Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
19. Known immunodeficiency syndrome.
20. Known asplenia or functional asplenia.
21. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \>10 mg/day) or immunosuppressive drugs within 30 days of day 0.
22. Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks prior to study agent administration.
23. Receipt of immunoglobulins and/or blood products within the past 6 months.
24. Previous receipt of an investigational malaria vaccine or MAb in the last 5 years.
25. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of an individual participating in the trial, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.
Part 2: Healthy Infants
Individuals meeting any of the following criteria will be excluded from study participation:
1. Body weight \<5.5 kg.
2. Behavioral, cognitive, or psychiatric disease in the parent and/or guardian that in the opinion of the investigator affects the ability of the parent and/or guardian to understand and comply with the study protocol.
3. Any fever (≥ 37.5°C, regardless of route) or acute illness within 7 days prior to randomization.
4. Clinically significant congenital anomaly or documented or suspected serious medical illness (e.g., history of epilepsy), serious congenital anomaly, or immediate life-threatening condition in the infant that may interfere with the ability to complete study requirements, as judged by the examining clinician.
5. Prior history of a suspected or actual acute medically life-threatening event.
6. Receipt of any blood products, monoclonal or polyclonal antibody/immunoglobulin (e.g., hepatitis B immune globulin, IV immunoglobulin), or anticipated use during the study.
7. Any suspected or actual life-threatening acute or chronic illnesses known in the mother during her pregnancy.
8. Parent or guardian study comprehension examination score of \<80% correct or per investigator discretion.
9. Hemoglobin, WBC, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
10. ALT or Cr level above the local laboratory-defined upper limit of normal. Individuals may be included at the investigator's discretion for "not clinically significant" values.
11. Mother and/or infant infected with HIV.
12. Sickle cell disease by testing. (Note: Known sickle cell trait is NOT exclusionary.)
13. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies.
14. Receipt of any investigational product within the past 30 days.
15. Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit. (Note: Past, current, or planned participation in observational studies is NOT exclusionary.)
16. History of a severe allergic reaction or anaphylaxis, including history of generalized urticaria and angioedema from prior allergic reactions.
17. Hypersensitivity to the active substances or to any of the excipients included in the vaccines.
18. Hypersensitivity to hepatitis B vaccines.
19. Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
20. Pre-existing autoimmune or antibody-mediated diseases including but not limited to systemic lupus erythematosus or autoimmune thrombocytopenia.
21. Known immunodeficiency syndrome.
22. Known asplenia or functional asplenia.
23. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \>10 mg/day) or immunosuppressive drugs within 30 days of day 0.
24. Previous receipt of the R21/Matrix-MTM or RTS,S/AS01 vaccine.
25. Receipt of a live or killed vaccine within the past 1 week prior to study agent administration.
26. Previous receipt of an investigational malaria vaccine or MAb.
27. Previous receipt of L9LS MAb by the mother.
28. Clinical signs of malnutrition.
29. Other condition(s) that, in the opinion of the investigator, might jeopardize the safety or rights of an individual participating in the trial, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.
Minimum Eligible Age
5 Months
Maximum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Sponsor Role
collaborator
Malaria Research and Training Center (MRTC)
UNKNOWN
Sponsor Role
collaborator
Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS)
UNKNOWN
Sponsor Role
collaborator
University of Sciences, Techniques, and Technologies of Bamako (USTTB)
UNKNOWN
Sponsor Role
collaborator
University of Washington
OTHER
Sponsor Role
collaborator
Indiana University School of Medicine, Indiana University
UNKNOWN
Sponsor Role
collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bickey H Chang, MD, MHA
Role: PRINCIPAL_INVESTIGATOR
LIG/NIAID/NIH
Kassoum Kayentao, MD, MPH, PhD
Role: PRINCIPAL_INVESTIGATOR
MRTC/FMOS/USTTB
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sotuba Malaria Research and Training Center (MRTC)
Sotouba, , Mali
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Mali
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025/183/CE/USTTB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Anti-malaria MAb in Kenyan Children
NCT05400655
COMPLETED
PHASE2
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
NCT02925403
COMPLETED
PHASE1/PHASE2
Infant Malaria Vaccine Schedule Optimization
NCT06879327
RECRUITING
PHASE2
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
NCT03896724
COMPLETED
PHASE1/PHASE2
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
NCT07009847
RECRUITING
A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B
NCT02600975
COMPLETED
PHASE1
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1
NCT02572388
COMPLETED
PHASE1
A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
NCT05357560
ACTIVE_NOT_RECRUITING
PHASE1
Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
NCT05135273
COMPLETED
PHASE1
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
NCT06507605
ACTIVE_NOT_RECRUITING
PHASE1
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
NCT00487916
COMPLETED
PHASE1
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
NCT07147400
RECRUITING
PHASE2
Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine
NCT00509158
COMPLETED
PHASE1/PHASE2
rCSP/AP10-602 [GLA-LSQ] Vaccine Trial
NCT03589794
COMPLETED
PHASE1
Trial to Assess the Efficacy of Malaria Vaccine PfCS 102
NCT01031524
COMPLETED
PHASE1/PHASE2
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
NCT06320535
ACTIVE_NOT_RECRUITING
PHASE1
R21/Matrix-M in African Children Against Clinical Malaria
NCT04704830
ACTIVE_NOT_RECRUITING
PHASE3
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
NCT00307021
COMPLETED
PHASE2
Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine
NCT00652275
UNKNOWN
PHASE2
Clinical Study of Meplazumab to Treat With Malaria
NCT04327310
WITHDRAWN
PHASE1
Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults
NCT05252845
COMPLETED
PHASE2
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
NCT07036159
RECRUITING
PHASE2
Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children
NCT01323972
COMPLETED
PHASE3
A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
NCT05790889
RECRUITING
PHASE1/PHASE2
R21/MM Dosing, Presentations, and Preservatives
NCT07194668
NOT_YET_RECRUITING
PHASE4